UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 2, 2021

EvePoint Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation) 000-51122

26-2774444 (I.R.S. Employer Identification No.)

(Commission File Number)

480 Pleasant Street Watertown, MA 02472 Principal Executive Offices, a

(Address of Pri and Zip Code)

(617) 926-5000 Registrant's Telepho lumber, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

П Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of	Trading	Name of each exchange
each class	Symbol(s)	on which registered
Common Stock, par value \$0.001	EYPT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01. Other Events.

On June 2, 2021, EyePoint Pharmaceuticals, Inc. posted an updated corporate presentation on its website at www.eyepointpharma.com. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01.	Financial Statements and Exhibits.
(d) Exhibits.	
Exhibit No.	Description
99.1 104	Corporate Presentation, dated June 2, 2021 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EYEPOINT PHARMACEUTICALS, INC.

 By:
 /s/ George O. Elston

 Name:
 George O. Elston

 Title
 Chief Financial Officer and Head of Corporate Development

Date: June 2, 2021



Forward Looking Statements

Various statements made in this presentation are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the potential benefits of our partnerships and strategic alliances with other companies, as well as the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a vital, novel twice-yearly treatment for wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion; preliminary financial information as of December 31, 2020; and our longer term financial and business goals, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the extent to which COVID-19 impacts our business; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ® and DEXYCU® and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for noninfectious uveitis affecting the posterior segment of the eye; the success of current and future license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; termination or breach of current license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; the potential for our preliminary financial information to change in connection with the finalization of our financial results for the fourth quarter and full year 2020; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized. COMPANY OVERVIEW

Proven technology driving pipeline growth

Compelling pipeline focused on retinal disease

- EYP-1901 potential twice yearly treatment for wet AMD, diabetic retinopathy and retinal vein occlusion
- YUTIQ50 potential twice yearly treatment for posterior uveitis
- Durasert[®] R&D collaborations

Durasert[®] - FDA validated drug delivery platform

- Sustained (zero-order kinetics) local delivery of drug product
- Provides constant and stable release of therapeutics in the eye over weeks, months or years
- Administered safely to thousands of patients' eyes across four FDA approved products including YUTIQ[®]

Commercializing two FDA-approved products - YUTIQ[®] and DEXYCU[®]

 Solid Q1 net product revenues and positioned for 2021 growth as COVID-19 restrictions ease across the US

TECHNOLOGY DURASERT® Platform

Proven sustained release intraocular drug delivery

TECHNOLOGY

DURASERT® Proven sustained release delivery



5 | EYEPOINT PHARMACEUTICALS

Four FDA-approved products with multiple programs in development

- Single intravitreal injection
- Continuous, stable release to the back of the eye provides consistent and reliable drug delivery over weeks, months or years
- Simple administration in physician's office

Approved products/Indications

- YUTIQ[®] (2018, EyePoint) -Posterior Segment Uveitis
- ILUVIEN[®] (2014, Alimera) DME
- RETISERT® (2005, B&L) Uveitis
- VITRASERT[®] (1996, B&L) -CMV retinitis

Development Candidates

- EYP-1901 for Wet AMD
- YUTIQ[®] 50 for Posterior Segment Uveitis
- Partner programs

Building on a Proven Platform


Retinal disease focused pipeline

PIPELINE PROGRAMS	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
 EYP-1901- anti-VEGF bioerodible Durasert Wet AMD 				
Diabetic retinopathyRetinal vein occlusion				
YUTIQ [®] 50 - chronic non-infectious uveitis				
Durasert Partners	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
Ophthalmology R&D collaboration				
Non-ophthalmology R&D collaboration				

EYP-1901 - Potential Twice a Year Anti-VEGF Treatment

Our goal is nothing short of transforming the treatment of wet AMD, diabetic retinopathy, and retinal vein occlusion

EYP-1901



Opportunity to transform the treatment of wet AMD

The need...

Currently, wet AMD patients often lose vision despite anti-VEGF therapy due to undertreatment

The EYP-1901 solution...


Potential twice yearly in-office injection of anti-VEGF therapy

- Anti-VEGF therapy (vorolanib) delivered via intravitreal injection using bioerodible Durasert
- Sustained, stable release may lead to better visual outcomes through steady receptor blocking


Real world need... today's wet AMD treatments still result in vision loss over time

PIPELINE

EYP-1901



RETROSPECTIVE, OBSERVATIONAL STUDY IN 2,227 PATIENTS WITH WET AMD




...including real world data from the U.S.

PIPELINE

EYP-1901

RETROSPECTIVE STUDY OF 3350 RANIBIZUMAB AND 4300 AFLIBERCEPT TREATMENT-NAIVE EYES WITH WET AMD



EYP-1901



The EYP-1901 solution


EYP-1901

 Intravitreal delivery of vorolanib using a bioerodible formulation of Durasert[®]

Vorolanib

- Tyrosine kinase inhibitor (TKI) studied as an oral therapy for wet AMD through Phase 2 with strong clinical signal and no significant ocular adverse events
- Blocks all 3 isoforms of VEGFR, the main driver of the proliferation of blood vessels that are the hallmark of wet AMD

VEGFR- vascular endothelial growth factor receptor



EYP-1901



A potent inhibitor of VEGFR

Vorolanib blocks VEGFR2 at the same level as sunitinib, a proven anti-VEGF therapy

BIOCHEMICAL SELECTIVITY (IC50, ng/mL)				
SUNITINIB	22.9			
VOROLANIB	22.9			

The inhibitor constant (Ki) of sunitinib for VEGFR is reported to be low (5 ng/mL), an indication of strong inhibition. Since Ki is related to IC50, similar inhibition Ki is expected for vorolanib.

IC50 – half maximal inhibitory concentration Head-to-head study completed by Tyrogenix

EYP-1901



EYP-1901 pre-clinical results


- 6-month rabbit GLP toxicology completed with no unexpected safety findings
- Efficacy and preliminary safety study completed in a laser CNV mini pig model

Results: dose-related activity and no observed toxicity


 Non-GLP rabbit PK and safety study demonstrated drug levels in vitreous and retina/choroid significantly above the IC50 for VEGFR2

15 | EYEPOINT PHARMACEUTICALS


CNV- choroidal neovascularization GLP – good laboratory practice PK - pharmacokinetics



EYP-1901




In-vivo release of vorolanib in rabbits measured over ~8 months




Linear decrease in residual drug in inserts indicates zero order drug release

EYP-1901



In-vivo cumulative % release of vorolanib in rabbits measured over ~8 months



R² for both doses indicates zero order release of drug at different dosing levels

EYP-1901



Oral vorolanib clinical results – Phase 1

Demonstrated clinical activity in wet AMD

Phase 1 trial design


- Open label, 24 weeks, dose escalation, no control, oral delivery; 80% of eyes enrolled previously treated; 4 eyes treatment naïve
- N=35; 25 completers

Phase 1 results

- BCVA was maintained to within 4 letters of baseline at the 24-week endpoint, or improved in all but 1 participant
- 60% (15/25) of patients required no rescue injection while on oral vorolanib therapy
- Excluding the 50 mg low dose, 72% of completers required no Anti-VEGF injection through the duration of the study (6 months)
- Mean OCT thickness in completers was reduced by -50 +/- 97 μm; Mean OCT thickness in treatment-naïve patients was reduced by ~80 μm

OCT – ocular coherence tomography Study performed by Tyrogenex

EYP-1901



20 | EYEPOINT PHARMACEUTICALS

Oral vorolanib clinical activity in wet AMD Phase 2 trial

Less rescue vs placebo for all doses with no ocular toxicity

For subjects followed ≥ 6 months	Placeb o n=33	50 mg n=34	100 mg n=30	200 mg n=26
Median number of anti-VEGF injections*	9.0	6.1	5.8	4.6
Percent of Patients w/ no rescue	2.6	7.5	10.3	20.5


Strict pre-defined rescue criteria with anti-VEGF therapy


- Any increase in fluid on OCT compared to screening visit 2 (~14 days after an IVT injection)
- New or increased macular hemorrhage by fundus photography

In the placebo group, 12.5% of subjects with unilateral disease at baseline developed exudative AMD in their fellow eyes by 52 weeks, compared with 3.8% (1/26), 0%(0/27) and 0%(0/23) in the 50 mg, 100 mg, and 200 mg groups, respectively.

* Normalized for number of months on study Study performed by Tyrogeix

EYP-1901 Phase 1 Trial





FDA Approved Commercial Products



CONTINUOUS CALM IN UVEITIS

Approved for the treatment of chronic non-infectious uveitis affecting the back of the eye

- Commercially launched in U.S. in 2019
- Patent protection to August 2027

Constant and stable release of fluocinolone with Durasert helps prevent uveitis flares for up to 3 years

LICENSE AGREEMENTS

Alimera Sciences, Inc. has rights for non-infectious posterior uveitis in the EMEA Rights for China, Hong Kong, Taiwan, Macau, Korea and certain SE Asia countries licensto Ocumenison with a royalty on sales payable to EvePoint



CONTINUOUS CALM IN UVEITIS

Chronic non-infectious uveitis causes blindness with every flare

60K–100K patients are suffering from uveitis in the U.S.

The need

- Flares can cause blindness
- 30,000 Americans become blind each year because of uveitis
- Uveitis lasts a lifetime and often affects people in middle age


The YUTIQ answer

- 3-year continuous treatment in a single injection that controls flares and preserves eyesight
- Simple administration in the physician's office
- Gives patients and physicians the confidence that comes with three years of assured compliance




Continuous 3-year delivery limits blindness-causing uveitis flares

Time to recurrence of uveitis within 36 months



0.18 mg YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg

CONTINUOUS CALM IN UVEITIS



Customer demand returning from COVID shutdowns



DEXYCU (dexamethasone intraocular suspension) 9%

TARGET THE SITE

Treatment of inflammation following ocular surgery

- Single long-lasting injectable treatment
 compared to low compliance eyedrop regimen
- Effective in preventing inflammation
 after cataract surgery with proven safety record
- Co-promoted with ImprimisRX, an established commercial organization in the cataract space

LICENSE AGREEMENT

Rights for China, Hong Kong, Taiwan, Macau, Korea and certain SE Asia countries license to Ocumension with a rovalty on sales payable to EvePoint



The U.S. cataract surgery market is large and growing


3.8 million cataract surgeries in 2018

The need

 As the baby boom generation ages, cataract surgery will become even more common The DEXYCU answer

- Today, eyedrops are the most common treatment after cataract surgery
- Patients forget to take their eye drops, leading to unnecessary complications
- Dexycu is injected into the eye at the time of surgery so compliance is not an issue

Customer demand returning from COVID shutdowns



PRODUCTS



DELIVERING INNOVATION TO THE EYE

Financial Summary

Solid cash position and growing revenues

- \$138.5 million of Cash on March 31, 2021, funds operations through Q4 2022
- \$6.8 million net product revenues in Q1 2021, a 45% increase over Q1 2020
- 2020 total revenues of \$34.4 million, including \$20.8 million of net product revenue
 - 2019 Total revenues of \$20.3 million including \$16.8 million on net product revenues

